Progeroid mice were chronically treated with a β3-AR agonist, which can rescue nestin+ niches in humans and mice with age-related myeloproliferative disorders (Arranz et al., 2014, Drexler et al., 2019) and has been recently suggested to rejuvenate normally aged HSCs (Maryanovich et al., 2018). This evidence concerns the gene NES and age.